Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Kairos Pharma, Ltd. (KAPA)
USD0.32
-0.02 (-6.47%)
US AMEX Healthcare Biotechnology
Address
2355 Westwood Blvd. 90064
Los Angeles, CA, US
Los Angeles, CA, US
CEO
John S. Yu
Website
kairospharma.com
IPO
2024-09-16
CIK 1962011 ISIN US48301N1046
Description
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.32
-0.02 (-6.47%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
134.7K
Beta
1.36
Float Shares
8.97M
Free Float %
41.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.33% | -18.60% | -20.68% | -22.41% | -41.34% | -34.65% | -25.16% | -82.15% | -82.15% | -82.15% | -82.15% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Buy
Price Targets & DCF
Current price
0.32
DCF (Unlevered)
0.24
-23.4%
DCF (Levered)
0.24
-23.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
7.41
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-30.4% Q1'26: -0.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-294.4% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+62.3% Q1'26: +32.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 EPS Ana. |
Dec 2027 2 EPS Ana. |
Dec 2028 3 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
—
— – —
|
—
— – —
|
—
— – —
|
27.80M
27.80M – 27.80M
|
55.58M
55.58M – 55.58M
+99.9% YoY
|
| EBITDA |
-1.58M
|
-5.29M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-1.74M
|
-5.45M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-2.60M
est: -1.59M (-63.7%)
|
-5.45M
est: -4.59M (-18.6%)
|
-7.00M
-7.00M – -7.00M
-52.4% YoY
|
-12.35M
-12.35M – -12.35M
-76.3% YoY
|
-14.25M
-18.41M – -10.09M
-15.4% YoY
|
-8.48M
-8.48M – -8.48M
+40.5% YoY
|
8.11M
8.11M – 8.11M
+195.7% YoY
|
| SGA |
1.77M
|
3.44M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-0.23
est: -0.14 (-64.3%)
|
-0.30
est: -0.25 (-20.3%)
|
-0.38
-0.38 – -0.38
-52.4% YoY
|
-0.67
-0.67 – -0.67
-76.3% YoY
|
-0.73
-1.00 – -0.55
-9.0% YoY
|
-0.46
-0.46 – -0.46
+37.0% YoY
|
0.44
0.44 – 0.44
+195.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 33.8K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
3
Sells
0
Shares acquired
6.7K
Shares disposed
—
Cash buys
3.00
Cash sales
—
Net activity
+6,700
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-08 | Yu John S | Director / Officer / 10% Owner | A-Award | A | COMMON STOCK | 190,840 | 0.00 | — | 230,105 | D | ↗ |
| 2025-10-08 | Singhvi Rahul | Director | A-Award | A | COMMON STOCK | 19,084 | 0.00 | — | 49,204 | D | ↗ |
| 2025-10-08 | Samuelson Doug | Officer | A-Award | A | COMMON STOCK | 152,672 | 0.00 | — | 293,039 | D | ↗ |
| 2025-10-08 | Murali Ramachandran | Officer | A-Award | A | COMMON STOCK | 152,672 | 0.00 | — | 299,529 | D | ↗ |
| 2025-10-08 | Keyoung Hansoo Michael | Director | A-Award | A | COMMON STOCK | 19,084 | 0.00 | — | 29,084 | D | ↗ |
| 2025-10-08 | Bhowmick Neil | Officer | A-Award | A | COMMON STOCK | 171,756 | 0.00 | — | 1,311,739 | D | ↗ |
| 2025-10-08 | Bae Hyun W. | Director | A-Award | A | COMMON STOCK | 19,084 | 0.00 | — | 73,370 | D | ↗ |
| 2025-09-16 | Keyoung Hansoo Michael | Director | A-Award | A | COMMON STOCK | 10,000 | 0.00 | — | 10,000 | D | ↗ |
| 2025-09-16 | Bae Hyun W. | Director | A-Award | A | COMMON STOCK | 10,000 | 0.00 | — | 54,286 | D | ↗ |
| 2025-01-01 | Yu John S | Director / Officer / 10% Owner | A-Award | A | COMMON STOCK | 14,000 | 0.00 | — | 5,355,838 | D | ↗ |
| 2025-01-01 | Murali Ramachandran | Officer | A-Award | A | COMMON STOCK | 14,000 | 0.00 | — | 147,057 | D | ↗ |
| 2025-01-01 | Bhowmick Neil | Officer | A-Award | A | COMMON STOCK | 14,000 | 0.00 | — | 1,139,983 | D | ↗ |
| 2024-12-10 | Singhvi Rahul | Director | — | — | COMMON STOCK | 0 | 0.00 | — | 30,120 | D | ↗ |
| 2024-11-25 | Murali Ramachandran | Officer | P-Purchase | A | COMMON STOCK | 200 | 1.59 | 318.00 | 133,057 | D | ↗ |
| 2024-11-22 | Samuelson Doug | Officer | P-Purchase | A | COMMON STOCK | 2,500 | 1.50 | 3.8K | 60,796 | D | ↗ |
| 2024-11-20 | Yu John S | Director / Officer / 10% Owner | P-Purchase | A | COMMON STOCK | 4,000 | 1.44 | 5.8K | 5,341,837 | D | ↗ |
| 2024-09-16 | Yu John S | Director / Officer / 10% Owner | — | — | COMMON STOCK | 0 | 0.00 | — | 5,337,837 | D | ↗ |
| 2024-09-16 | Samuelson Doug | Officer | — | — | COMMON STOCK | 0 | 0.00 | — | 58,296 | D | ↗ |
| 2024-09-16 | Murali Ramachandran | Officer | — | — | COMMON STOCK | 0 | 0.00 | — | 132,857 | D | ↗ |
| 2024-09-16 | MAZANET ROSEMARY | Director | — | — | COMMON STOCK | 0 | 0.00 | — | 0 | D | ↗ |
| 2024-09-16 | Keyoung Hansoo Michael | Director | — | — | COMMON STOCK | 0 | 0.00 | — | 0 | D | ↗ |
| 2024-09-16 | Bhowmick Neil | Officer | — | — | COMMON STOCK | 0 | 0.00 | — | 1,125,983 | D | ↗ |
| 2024-09-16 | Bae Hyun W. | Director | — | — | COMMON STOCK | 0 | 0.00 | — | 44,286 | D | ↗ |
Executive team
Top executives
Shares Outstanding
21.41M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Doug Samuelson | 14.7K | — | 123.0K | — | — | — | 137.7K | 89.35% | ↗ |
| 2 | 2024 | John S. Yu | 51.3K | — | 34.4K | — | — | — | 85.7K | 40.17% | ↗ |
| 3 | 2024 | Neil Bhowmick | 29.3K | — | 34.4K | — | — | — | 72.8K | 47.34% | ↗ |
| 4 | 2024 | Ramachandran Murali | 23.5K | — | 34.4K | — | — | — | 63.9K | 53.90% | ↗ |
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| John S. Yu | Chief Executive Officer, Chairman & Secretary | 287.5K | — |
| Neil A. Bhowmick | Chief Scientific Officer | 156.3K | — |
| Ramachandran Murali | Vice President of Research & Development | 127.5K | — |
| Douglas W. Samuelson | Chief Financial Officer | 112.5K | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for KAPA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
